Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shan baoen
Shanghai, Shanghai, Chinasunboundbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sunbound is a clinical-stage biotechnology company focused on the discovery and development of next-generation small molecule therapeutics for oncology, with a particular emphasis on the RAS/MAPK signaling pathway. The company leverages its structure-based drug design platform to develop highly selective inhibitors targeting difficult-to-drug mutations such as KRAS G12D and KRAS G12V. Sunbound's lead programs are currently undergoing clinical evaluation for the treatment of advanced solid tumors, including non-small cell lung cancer and pancreatic cancer. By targeting specific oncogenic drivers, the company aims to provide more effective treatment options for patients with limited therapeutic alternatives.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Shan baoen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shan baoen.